Has Paola Rios Florez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,410 in general payments to Paola Rios Florez, MD across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paola Rios Florez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paola Rios Florez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paola Rios Florez, MD

Endocrinology, Diabetes & Metabolism · Altoona, PANPI 1205322336

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Amryt Pharma Holdings Ltd at 25.0% of the total.

$1,410in general payments, 2019–2025

Across 21 payments — averaging $67.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amryt Pharma Holdings Ltd$352
AstraZeneca$281
Medtronic$241
Insulet Corporation$175
Bayer$120
Johnson & Johnson$102
plus $141 from 2 others

What the payments were for

Food & beverage$1,410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amryt Pharma Holdings Ltd	3	$352
AstraZeneca(2 entities)	3	$281
Medtronic	2	$241
Insulet Corporation	2	$175
Bayer	1	$120
Johnson & Johnson	8	$102
BETA Bionics, Inc.	1	$77
Amgen	1	$64

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,410 in reported general payments places this provider in the 55th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$53,031

Medicare patients

196

Services billed

843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	232	$353,120
JardianceEmpagliflozin	136	$152,243
MounjaroTirzepatide	69	$112,650
TrulicityDulaglutide	65	$76,363
Humulin R U-500 KwikpenInsulin Regular, Human	45	$74,177
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	45	$52,756
Humalog Kwikpen U-200Insulin Lispro	22	$37,132
Humalog Kwikpen U-100Insulin Lispro	96	$35,636
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	211	$25,858
TradjentaLinagliptin	20	$18,402
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	14	$16,358
Tresiba Flextouch U-200Insulin Degludec	11	$15,278
Novolog FlexpenInsulin Aspart	40	$12,543
JanuviaSitagliptin Phosphate	13	$12,281
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	24	$11,287

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Altoona

Serge JabbourPhiladelphia$1.2M
Vijay BahlPittsburgh$998K
Geraldo SaavedraWhitehall$698K
Jane MayrinPhiladelphia$628K
Stephan KowalykGreensburg$591K
Matthew KaneWest Chester$577K
Intekhab AhmedPhiladelphia$528K
Swarna VarmaPittsburgh$520K
James DickeHanover$425K
Mitchell LazarPhiladelphia$358K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →